Potential Synergistic Effect between Niraparib and Statins in Ovarian Cancer Clinical Trials.

IF 2 Q3 ONCOLOGY Cancer research communications Pub Date : 2025-01-01 DOI:10.1158/2767-9764.CRC-24-0191
Hailei Zhang, Anna Rutkowska, Antonio González-Martín, Mansoor R Mirza, Bradley J Monk, Ignace Vergote, Bhavana Pothuri, Whitney A Spannuth Graybill, Carsten Goessel, Olena Barbash, Giovanna Bergamini, Bin Feng
{"title":"Potential Synergistic Effect between Niraparib and Statins in Ovarian Cancer Clinical Trials.","authors":"Hailei Zhang, Anna Rutkowska, Antonio González-Martín, Mansoor R Mirza, Bradley J Monk, Ignace Vergote, Bhavana Pothuri, Whitney A Spannuth Graybill, Carsten Goessel, Olena Barbash, Giovanna Bergamini, Bin Feng","doi":"10.1158/2767-9764.CRC-24-0191","DOIUrl":null,"url":null,"abstract":"<p><strong>Significance: </strong>The presented retrospective analysis suggests, to the best of our knowledge for the first time, a potential significant interaction between statins and niraparib in clinical settings. Nevertheless, further investigations are required to gain a better understanding of the potential clinical benefit.</p>","PeriodicalId":72516,"journal":{"name":"Cancer research communications","volume":" ","pages":"178-186"},"PeriodicalIF":2.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11775730/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer research communications","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1158/2767-9764.CRC-24-0191","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Significance: The presented retrospective analysis suggests, to the best of our knowledge for the first time, a potential significant interaction between statins and niraparib in clinical settings. Nevertheless, further investigations are required to gain a better understanding of the potential clinical benefit.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
卵巢癌临床试验中尼拉帕尼和他汀类药物的潜在协同效应。
本研究探讨了聚腺苷5′-二磷酸[ADP]-核糖)聚合酶(PARP)抑制剂尼拉帕尼(Zejula®)与伴用药他汀类药物之间的潜在临床协同作用,探讨了它们对卵巢癌患者无进展生存期(PFS)的联合影响。我们回顾性分析了尼拉帕尼在卵巢癌中的注册临床试验,以调查尼拉帕尼和他汀类药物之间潜在的相互作用。在PRIMA试验中,与安慰剂组相比,接受尼拉帕尼的患者表现出PFS的改善(风险比=0.62;P
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Safety and efficacy of copanlisib in combination with nivolumab: a Phase Ib study in patients with advanced solid tumors. A Phase 2 Study of Sotigalimab, a CD40 Agonist Antibody, Plus Concurrent Chemoradiation as Neoadjuvant Therapy for Esophageal and Gastroesophageal Junction Cancers. Phase 1b study of immunocytokine simlukafusp alfa (FAP-IL2v) combined with pembrolizumab for treatment of advanced and/or metastatic melanoma. Loss of NF1 Accelerates Uveal and Intradermal Melanoma Tumorigenesis, and Oncogenic GNAQ Transforms Schwann Cells. Ternary Complex Components Responsible for Rapid LDL Internalization as Biomarkers for Breast Cancer Associated with Proliferation and Early Recurrence.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1